Reimbursed Care Access in Myanmar

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Myanmar’s Ministry of Health notifications explicitly list Psilocybe (psilocybin-containing) mushrooms among declared narcotic plants, and the 1993 Narcotic Drugs and Psychotropic Substances Law frames possession, production and trafficking under penal provisions; medical use is only possible with explicit Ministry-level permission or within authorised programmes. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA and its analogues are regulated as psychotropic substances under Myanmar’s narcotics framework and are subject to severe criminal penalties for unauthorised manufacture, supply or possession; there is no public reimbursement or authorised clinical access outside approved research. #

Esketamine (Spravato®) is not documented as an authorised, marketed, or reimbursed product in Myanmar public sources; there is no evidence of national marketing authorisation or inclusion on Myanmar reimbursement lists. Globally, esketamine has received regulatory approvals in multiple jurisdictions (e.g., FDA, EMA) for treatment‑resistant depression and comes with special distribution/administration controls, but Johnson & Johnson / Janssen rollout information and regulatory approvals do not list Myanmar as a country of known commercial approval or public reimbursement programme, and no Myanmar regulatory announcement for Spravato® was identified in national sources. Consequently, esketamine is not available as a standard reimbursed therapy in Myanmar and—if used at all—would require explicit Ministry of Health approval, import authorisation or participation in an authorised clinical study. # #

Ketamine is an accepted medical anaesthetic and analgesic within Myanmar’s health system and is listed on the WHO Model List of Essential Medicines as an injectable anaesthetic, indicating it is an established component of hospital pharmacotherapy and emergency care. In Myanmar, the Narcotic Drugs and Psychotropic Substances legal framework allows use of narcotic drugs and psychotropic substances for medical treatment under Ministry of Health supervision and registration; accordingly, ketamine is used in public and private hospitals for anaesthesia, obstetric care and emergency procedures and is present in clinical supply chains (while also being subject to law‑enforcement action when diverted). Procurement and reimbursement detail (public insurance coverage) is limited in public sources: Myanmar does not operate a universal, government‑wide pharmaceutical reimbursement programme comparable to OECD national formularies, so ketamine’s payment is typically through hospital budgets (public hospitals) or private patient payment/insurance where private coverage exists. Off‑label psychiatric use of ketamine (e.g., for depression) is practiced in some jurisdictions globally but is not a formally reimbursed, nationally recognised psychiatric indication in Myanmar; such use would be private/off‑label and require specialist oversight and likely out‑of‑pocket payment. Key sources: WHO EML listing for ketamine and Myanmar narcotics law allowing medical use under Ministry of Health notification; recent reporting also shows substantial illicit seizures of ketamine in Myanmar, underscoring diversion risks. # # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and DMT‑containing preparations) fall within psychotropic substances controlled by Myanmar’s narcotics notifications; any clinical research would require Ministry of Health and relevant regulatory approvals. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of authorised therapeutic pathways or reimbursement for 5‑MeO‑DMT in Myanmar; possession or supply is treated under psychotropic/narcotics regulations. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not recognised in Myanmar clinical practice or reimbursement, and any use would require explicit regulatory permission. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although ayahuasca as a botanical brew is not separately regulated at the international scheduling level, its principal psychoactive constituent (DMT) is controlled, and Myanmar’s legal framework treats DMT and related preparations as psychotropic/narcotic substances, so ayahuasca has no authorised therapeutic or reimbursed status in Myanmar. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Notably, Myanmar’s Ministry notifications explicitly declared peyote (mescaline‑containing cactus) among prescribed narcotic plants, meaning mescaline and mescaline‑containing plants are regulated; there is no authorised medical programme or reimbursement for mescaline. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C‑series phenethylamines and analogous novel psychoactive substances are treated as psychotropic/narcotic substances in Myanmar’s regulatory framework; there is no authorised medical access or reimbursement. #